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In one article, photodynamic therapy (PDT) was commended as the most suitable method for cancer 
therapy in the Developing World. PDT is cost effective and simple to use. Unlike chemotherapy, no 
special training is required for nurses, and no post treatment course in intensive care. No engineer, 
computerized dosimetry computations, or additional costs for isotope re-treatment are required, as in 
radiotherapy. There are no blood transfusions, or sophisticated operating theatres, as in surgery. 
Ironically, it is in the developing world that there appears to be very little awareness of and practice of 
PDT. Cancer sufferers are thus limited to chemotherapy, radiotherapy and surgery procedures that are 
relatively complex and costly, without distinctive advantage in cure or palliation. Is it possible that the 
low level of clinical practice in PDT in the developing world is related to the low level of articulation of 
what is admittedly a relatively new modality? However, this slow emergence of clinical practice in PDT 
when compared with advances in its developmental research was also observed in the developed 
world in the last two centuries or so. The purpose of this article was to advance the articulation of PDT, 
primarily among basic science researchers, clinicians and clinical scientists in the developing 
countries. It is also to advance the emerging new frontiers of the clinical applicability of the processes 
of photodynamic reactions in the fight against infectious disease epidemics, which are a more 
common occurrence in the developing world countries.  
 





Photodynamic therapy (PDT) has been defined as the 
combined effect of a photosensitizing drug and light to 
produce biological damage of therapeutic value, under 
conditions where either the light or the drug operating 
alone have no effect (Bonnett and Berenbaum, 1989a). 
The procedure involves administration of the photo-
sensitizing drug followed by irradiation at a wavelength 
corresponding to an absorbance band of the sensitizer. In 
the presence of oxygen, a series of events lead to direct 
tumor cell death, damage to the microvasculature, and 
induction of a local inflammatory reaction (Agostinis et al., 
2011). Clinical studies revealed that PDT can be curative, 
particularly in early stage tumors. The approach has 
aroused considerable interest in scientific, medical and 
commercial circles in recent times, partly because it is 
conceptually very exciting, but also because there is no 
doubt that it works in destroying malignant or otherwise 
problematic tissue. The basis for PDT lies with two 
remarkable properties of the photosensitizing drugs that 
are used in the approach-their preferential accumula-
 





tion in cancer tissue and the subsequent light triggered 
toxicity of the drugs (Henderson and Dougherty, 1992). In 
the last two decades, exponentially increasing basic 
research has appeared in the literature in the applications 
of photodynamic reactions against various diseases 
caused by bacterial colonization (Schastak et al., 2010; 
Dai et al., 2009), fungal infection (Lyon et al., 2011) and 
parasites (Barbosa, 2012), that are faced by many clinics 
in developing world countries, as well as those caused by 
entomological vermin (Amor and Jori, 2000, 2001). These 
have expanded the applicability of the photodynamic 
reaction beyond its initial focus on cancerous conditions 
based on destroying malignant or otherwise problematic 
tissue.The patent issued in 1992 for the photodynamic 
inactivation of viruses in blood cell-containing composi-
tions (Horowitz et al., 1992), appears to have triggered 




HOW DOES PDT WORK IN DESTROYING CANCER? 
 
In the systemic approach, often used for deep-seated 
tumours, the patient is injected intravenously with a 
suitable preparation of the drug and confined to the dark. 
A period of time is allowed for the drug to accumulate 
preferentially in cancer tissue. The period varies from 
drug to drug, from as little as 3 h, to more than 72 h. After 
this period, most of the drug is in the cancer tissue. The 
differential in drug concentration between cancer tissue 
and the rest of the body varies from drug to drug, from as 
low as 6:1 to more than 20:1. A suitable dose of light is 
then administered. This presents little challenge for 
external cancers. For internal ones, optic fibre light 
delivery and guidance devices are often used. Drug rich 
tissue is destroyed immediately. Cancer tissue 
destruction persists without affecting drug deficient 
tissue. When the drug is completely cleared from the 
body the patient is allowed back into normal light 
environments (Okunaka et al., 1995; Serebrovskaya et 
al., 2009). For topical cancers such as skin cancers, 
topical ALA-PDT is more appropriate. Dead skin around 
the affected area is removed with an abbraisive tool. A 
cream formulation of ALA is applied, followed, after a 
suitable period of 6 to 24 h, by application of laser light. 
Necrosis of cancerous tissue starts immediately 
(Monfrecola et al., 2009).  
Cancer tissue destruction is achieved because the drug 
absorbs the energy of light, generating highly reactive 
species, which cause biological damage (Neely et al., 
1988; Hartley et al., 1988). The extremely short lifetime of 
singlet oxygen within the biological environment means 
that the treatment is highly localized, without systemic 
side effects. For this reason, PDT can be especially 
effective in disease sites close to vital organs, such as in 
cancers of the head, neck and the brain (Brown, 1999; 
Biel, 2007; Wilson and Patterson, 2008). Although necrosis 




necrosis has been recognized as the major photo-
dynamic response, apoptosis has been described in PDT 




THE MECHANISM OF PDT 
 
Although tissue damage resulting from porphyrin 
photosensitised photodynamic action is generally 
regarded as arising from a number of different 
mechanisms, the major pathway is the singlet oxygen 
also referred to as the type II mechanism (McRobert et 
al., 1989; Mroz et al, 2010; Mroz et al, 2011) (Figure 1). 
The mechanism involves photo-excitation of the 
photosensitizer from its singlet ground state to its first 
singlet excited state, followed by intersystem crossing to 
the triplet excited state, whereupon it photosensitizes 
triplet ground state oxygen to give singlet excited state 
oxygen, a highly reactive species, which has been 
reported as the cause of chemical degradation for a 
variety of biological systems (Neely et al., 1988; Rezka, 
1990; Mroz et al., 2011). This is illustrated in the 
Jablonski diagram of Figure 2, and in the mechanistic 
reaction equations 5 to 7. Some of the targets of singlet 
oxygen, for example, unsaturated lipids, cholesterol and 
certain amino acid side chains in proteins are important 
membrane components. It is thought that photochemical 
changes in these components are an important cause of 
tissue damage (Candide et al., 1998; Yanina et al., 
2012). Some of the reported consequences of this 
cytotoxic action include, for example, inhibition of 
membrane bound enzymes, and interference with 
membrane transport resulting in impairment of the vital 
membrane permeability control barriers (Rezka et al., 
1990; Goes et al., 1998; Hsieh et al., 2003; Weyergang et 
al., 2008). 
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Figure 1. Jablonski diagram showing the formation of singlet oxygen via a porphyrin triplet state with energy 
greater that the oxygen singlet state of 94.5 kJ. White arrows represent electron pairs, parallel arrows 
represent triplet states while antiparallel ones represent singlet states. The two large antiparallel arrows 




indicates excited states. Scheme 1 shows the two major 
mechanisms for photodynamic reactions, type I and II. 
In the radical mediated mechanism also referred to as 
type I, the photosensitizer is excited to the triplet state as 
in the first step of the singlet oxygen mechanism, 
whereupon it interacts directly with biomolecules causing 
irreversible chemical changes in them. The triplet state 
photosensitizer, for example, may remove an electron 
from a lipid molecule in cell membranes giving a lipid 
cationic radical and a photosensitizer anionic radical 
(Girotti, 2001). The anionic photosensitizer radical may 
then interact with oxygen to produce a superoxide radical 
and a singlet state photosensitizer.  
The cationic lipid radical may lose a proton to give a 
neutral radical. Such lipid molecule radicals may 
eventually react with a variety of protein molecules 
embedded in the membranes. The superoxide radical 
can generate such species as hydrogen peroxide. These 
two mechanisms are referred to as type I and II (Singh et 
al., 1992; Feix et al., 1991; Feix and Kalyanaraman, 
1991; Mroz et al., 2010, 2011). 
 
 
PDT DRUGS IN USE 
 
The majority of PDT drugs belong to the unique family of 
macrocyclicporphyrin, and phthalocyanine type of 
compounds (Kessel, 1995; Oleinick, 2001). A number of 
drugs have been licensed for use in PDT (Dougherty, 
2000; Oleinick, 2001). Photofrin currently enjoys the 
widest approval, in a number of countries, including 
Canada, Denmark, France, Finland, Germany, Iceland, 
Italy, Japan, Netherlands, United Kingdom and the USA, 
for a variety of cancers, including lung, oesophageal, 
bladder, gastric, cervical, skin and brain cancer (Brown, 
1996, 1999). Photofrin belongs to the first generation of 
PDT drugs in that it is a mixture of a number of porphyrin 
compounds that are ether and ester linked oligomers of 
haematoporphyrin, its composition is not stable and may 




Second generation drugs now in use 
 
Second generation drugs now in use, pre-clinical and 
clinical trials include Foscan from Scotia (Bonnett and 
Djelal, 1993), Visudyne from QLT (Levy et al., 1994), 
Lutex from Pharmacyclics (Woodburn et al., 1998), Pc4 
from Case Western Reserve (Ahmad et al., 1998), 
Purlytin from Miravant (Kaplan et al., 1998), NPe6 from 
Nippon (Taber et al., 1998), HPPH from Roswell Park 
Cancer Institute (Dougherty, 1998) and amino laevulinic 
acid from DUSA (Marcus, 1996). A number of second 
generation drugs are under development including 
boronated porphyrins, which are designed for use in boron 
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neutron capture therapy (Hill et al., 1995). 
 
 
Some of the desirable features of second generation 
drugs  
 
Some of the desirable features of second generation 
drugs include lack of toxicity in the dark, selective uptake 
by cancer tissue and short-term retention to avoid the 
persistence of photosensitivity. Other important features 
include triplet state energy greater than 94 kJ/mol, 
intermediate lipid water partition coefficient (Engelmann, 
2007; Mizuno et al., 2011), pure single chemical 
compounds, and light absorption in the red or far red part 
of the visible spectrum. The last feature derives from the 
high depth of penetration of tissue by radiation in the red 
region of the light spectrum and lower energy, and it is 
being used as a design feature for third generation drugs 




(Bonnett and Berenbaum, 1989b; Kinsella, 2001). 
 
 
Third generation photosensitisers are in 
experimental development  
 
Third generation photosensitisers are in experimental 
stages. These have two chromophores; one 
chromophore rapidly picks up two photons in the infrared 
region of the light spectrum and converts them into a 
single photon. This photon is then absorbed by the 
sensitizer’s second porphyrinic chromophore. Such 
sensitisers are expected to be able to generate singlet 
oxygen from the triplet state of the porphyrinic 
chromophore of the photosensitizer, even though infrared 
excitation is being used. Experiments on this work started 
in the early nineties (Sessler et al., 1993; Wang, 2004; 





A number of variations of PDT have been reported, 
including normal PDT, ALA-PDT, and radiation 
sensitization. Normal PDT has already been described. In 
ALA-PDT (Pollock et al., 2004; Wiegel and Wulf, 2006; 
Gaál et al., 2012) amino laevulinic acid (ALA) is 
administered either orally or topically. The high 
concentration levels of ALA disrupt the feedback 
controlled haeme biosynthesis and this leads to an 
abnormally high, and phototoxic level of protopophyrin IX, 
in excess of the enzymatic rate of chelation with Fe
2+
. 
Irradiation in the presence of this high level of 
protopophyrin IX in cancer tissue with suitable light leads 
to the normal PDT response (Kennedy and Pottier, 1992; 
Marcus, 1996; Van den Berg et al., 1999). In radiation 
sensitization (Franken et al., 2012), the treatment of 
cancer with boron containing porphyrin or phthalocyanine 
drugs based on the reaction of the stable 
10
B isotope with 
slow neutrons, which generates an ionizing fluence of 
high energy-particles together with the recoil 
7
Li 
particles, has been demonstrated. This type of radiation 
sensitization is known as boron neutron capture therapy 
(BNCT) (Barth et al., 1990). Recently BNCT was shown 
to be an effective alternative treatment modality for 
patients with glioma (Wang et al., 2010).  
The scope of PDT has been extended beyond cancer 
therapy to include viral infections (Levy and Obochi, 
1996), bacterial infections (Jori and Tonlorenzi, 1999) 
and other conditions (Hunt et al., 1998). The application 
of PDT to treat age related macular degeneration was 
approved in the USA and Canada (Husain et al., 1997) 
and the potential application of PDT to treat rheumatoid 
arthritis was demonstrated (Hunt and Chan, 2000). 
Applications of PDT for environmental antiseptic 
purposes (Bonnett et al., 1990; Brovko, 2009) and as 
pesticides (Wingo et al., 1997, 1998a, b; Amor and Jori, 





ALARMING CANCER STATISTICS 
 
While incidence and mortality rates for most cancers are 
decreasing in developed countries, they are increasing in 
several less developed countries because of adoption of 
unhealthy western lifestyles such as smoking and 
physical inactivity and consumption of calorie-dense food 
(Jemal et al., 2010). The world health organization 
(WHO, 2008a; b) lists sixteen malignant neoplasms 
including mouth and oropharynx, esophagus, stomach, 
colon and rectum, liver, pancreas, trachea and bronchus 
and lung, melanoma and other skin, breast, cervix uteri, 
corpus uteri, ovarian, prostate, bladder, lymphomas and 
multiple myeloma, and leukemia. The top cancers in the 
world today are lung, stomach, breast, colon and rectum. 
The most common among men are prostrate, lung and 
bronchus, colon and rectum cancers. Among women, the 
top three are breast, lung and bronchus, and colon and 
rectum cancers (Amor and Jori, 2001). 
In 1990, the top five cancers among male South 
Africans were basal cell skin, prostate gland, 
oesophagus, lung and squamous cell skin cancers. 
Among females, they were cervix, breast, basal cell skin, 
squamous cell skin; and oesophagus cancers (Sitas, 
1992, 1994; Du Plessiset al., 1999). However, as shown 
in Figure 3, WHO data for the period ending in 2008, 





Although the clinical practice of PDT was slow to catch 
up with advances in drug development, clinical trials and 
research, it has subsequently moved so rapidly in the 
developed world that a number of specialized and 
accredited training programs are now available (Sitas, 
1992, 1994; Du Plessis et al., 1999). Traditional training 
in clinical PDT takes the medical student through 
classroom experiences, supervised hospital experiences, 
and through standardized examinations. In the class-
room, students learn the principles of PDT, the drugs 
used, their mode of activity, metabolism and safety. They 
learn the physics and safety of light and of the laser 
systems used. They learn about the animal and cell 
models used in preliminary testing of new drugs. Clinical 
education on PDT includes ear, nose and throat (ENT), 
oral, dermal, urological, bronco-oesophageal and neuro-
logical indications, and are led by the respective experts. 
PDT complications also form part of the curricula. The 
power of video-based demonstrations of PDT derives 
from the condensation of a treatment, which ordinarily 
takes a number of days to a single video session. Such a 
demonstration should prepare students for a series of live 
demonstrations by various experts. The examination 
takes the form of theory and practice to test both 
knowledge and ability. The certificates awarded enjoy 
recognition by a growing number of respected societies 
for standards of ethics, practice and safety (Dilkes, 1999).  






Figure 3. Rankings of malignant neoplasms in South Africa by the end of 2008. The data was obtained from 
the update of estimates of deaths using the methods of previous revisions carried out by WHO for 2002 and 
2004 (Lopez et al., 2006; WHO, 2004). Mortality estimates are based on analysis of latest available national 
information on levels of mortality and cause distributions as at the end of 2010 together with latest available 




Towards clinical practice 
 
A frequently asked question is "If PDT is so good, why 
then is it taking so long to reach the clinic?" There are no 
easy answers. It is a new modality and the various ethical 
and administrative agencies have proceeded cautiously 
in sanctioning its clinical use. There have also been a 
number of competing modalities developed during the 
same period. PDT has thus had to demonstrate 
superiority or at least comparability. Finally, the number 
of treatment parameters to be specified in PDT is 
significantly more than in conventional or competing new 
modalities for cancer. However, although photofrin has 
achieved widespread approval, a number of significantly 
superior new drugs are now being examined for approval 
for a wider variety of indications. This is expected to 
catapult PDT well into the clinic in this decade. It is 
generally agreed however that although PDT will prove 
extremely useful in this century, there is a great need for 
a great number of clinicians to move into the center stage 
of the modality (Kato et al., 1999). In the developing 
world, this simply means introducing PDT in the clinic 
through awareness and appropriately designed short 
learning programmes.  
 
 
Awareness of PDT 
 
The awareness and acceptance of PDT among clinicians  
has always been a major issue. A study suggested that in 
the UK, the percentage of clinicians that are not aware of 
PDT is less than 20%. This study also showed that the 
frequency of clinical publications in PDT worldwide has 
doubled over the past twelve years. However, the study 
also showed that the percentage of PDT related abstracts 
at the annual meeting of the British Association of 
dermatologists was less than 0.05%, and that the 
percentage of PDT related abstracts at the annual 
meeting of the American Society of Clinical oncology was 
less than 0.005% (Brown, 2000). How can the profile of 
clinical PDT be raised? Some of the key suggestions 
include the organization of more robust, multi-centre 
clinical trials, increased marketing by PDT companies, 
wider questionnaire research to ascertain levels of 
interest and understanding, publication of simple and 
informative booklets for clinicians, publication of simple 
handbooks on PDT, wider circulation of PDT magazines 
among clinicians, increase clinical content of PDT web-
sites, and more PDT work to be published in specialist 
clinical journals (Brown, 2000).  
 
 
A CASE FOR PDT AND VARIATIONS IN THE 
DEVELOPING WORLD 
 
In the Developing World, there is a need to start the 
debate on PDT among clinicians, perhaps by conducting  




extensive PDT awareness campaigns and research. This 
should provide the basis for rational programming and 
capital investment in key centres of excellence, in order 
to launch a focused effort in PDT. It would then remain 
for this effort to demonstrate the performance of PDT 
against traditional modalities, the ultimate acid test, as in 
the Developed World. In addition, these centres of 
excellence should provide platforms for the exploration of 
emerging applications of PDT in areas other than cancer 
and other accepted applications.  
 
 
Breast cancer  
 
Breast cancer is a significant oncological issue because it 
is diagnosed in over a million patients a year. Treatment 
paradigms have shifted to emphasize protocols that 
require expensive equipment and treatment rooms, 
aimed at preserving the breast. However, due to a lack of 
equipment and facilities this option is only rarely offered 
to poverty stricken patients like those in the Developing 
World. PDT may play a role in allowing for greater breast 
conservation, based in part on the emerging success of 
partial breast radiation (Allison et al., 2006). 
 
 
PDT against antibiotic resistant bacteria  
 
PDT has been studied to demonstrate its effectiveness in 
eradicating Gram- positive and negative antibiotic 
resistant bacteria including those in biofilm formations 
(Biel, 2010). The antibacterial effectiveness of PDT is an 
important issue for the developing world where bacterial 
infections pose a more serious threat to healthcare than 
in the developed world. PDT for localized infections was 
demonstrated by Dai et al. (2009), who observed that the 
advantages of PDT include equal killing effectiveness 
regardless of antibiotic resistance, and the absence of 
induction of resistance to PDT treatment and that the 
disadvantages include the cessation of the antimicrobial  
effect when the light is turned off, and less than ideal 
selectivity for microbial cells over host tissue. Unlike 
anticancer PDT, microbial selectivity therefore remains a 
research issue in antimicrobial photodynamic therapy. 
 
 
Photodynamic antimicrobial chemotherapy 
 
Given the ever increasing problem of antibiotic resistance 
in nosocomial pathogens, it is important to promote 
alternate technologies that may be more effective than 
current antibiotics. Photodynamic antimicrobial chemo-
therapy (PACT), a technology based on the use of a 
photosensitizer activated by visible light illumination and 
found to be effective against most types of microbial 
pathogens, including those resistant to antibiotics was 





been extensively studied and has demonstrated efficacy 
in the laboratory, in several animal models and in the 
treatment of periodontal disease and additional clinical 




PACT in wound management 
 
The loading of the photosensitizersmeso-tetra(N-methyl-
4-pyridyl)porphyrin tetra tosylate (TMP), methylene blue 
(MB) and TMP with sodium dodecyl sulphate (SDS) into, 
and release from hydrogels composed of the 
polyelectrolyte poly(methyl-vinyl-ether-co-maleic acid) 
crosslinked in a 2:1 ratio with polyethylene glycol (PEG) 
were investigated as a potential rapid photodynamic 
antimicrobial chemotherapy (PACT) treatment for in-
fected wounds using iontophoresis as a novel delivery 
method (Fallows et al., 2012). These results support the 
contention that the iontophoteric delivery of TMP and MB 
using anti-adherent, electrically-responsive, PEG-cross-
linked PMVE/MA hydrogels is a potential option in the 
rapid PACT treatment of infected wounds. This metho-
dology may be ideal for the treating of wounds in 
remotely located clinics in third world countries as it is 
rapid and effective, generally requiring a single appli-
cation and no further dressing and retreatment.  
 
 
PACT for fire burn wounds 
 
Informal settlements are a common feature of developing 
world countries. Fire burns are very common in the clinics 
that serve patients from informal settlements. Burns are 
one of the most common injuries in both children and 
adults (Brigham and McLoughlin, 1996). The primary 
goals of acute burn wound management are prevention 
of infection and the promotion of optimal wound closure 
by re-epithelialization. With the open method of wound 
care for second degree burns, antimicrobial agents are 
routinely used to minimize bacterial proliferation and 
fungal colonization (Harry et al., 2005). Pseudomonas 
aeruginosa is considered one of the most notorious 
pathogens that represent life-threatening risk in 
nosocomial environments, mainly in patients with severe 
burns. In vitro tests showed that antimicrobial 
photodynamic therapy (aPDT) was effective against a 
clinical isolate of P. aeruginosa with resistance to multiple 
antibiotics (Hashimoto et al., 2012). 
 
 
The absence of the development of bacterial 
resistance  
 
The significant promise of PACT and aPDT for 
developing countries is not only its effectiveness against 





teeth with apical periodontitis (Silva et al., 2012) but also 
the absence of the development of bacterial resistance 
(Tavares et al., 2010).  
Even as PDT quickly embraced nanotechnology for 
benefits such as drug administration, delivery and 
enhancement of efficacy, the effectiveness of nano-
particle based aPDT was demonstrated with the study of 
the in vitro effects of poly(lacticco-glycolic acid) (PLGA) 
nanoparticles loaded with thephotosensitizer methylene 
blue (MB) and light against Enterococcus faecalis (ATCC 
29212) (Pagonis et al., 2010). 
 
 
Other areas proposed for clinical application 
 
Clearly therefore, PDT appears to represent an effica-
cious alternative modality for the treatment of localized 
microbial infections by using either in situ or topical 
application of the photosensitizer followed by irradiation 
of the photosensitizer-loaded infected area, using a 
wavelength of light that matches the red region 
absorption maxima of the photosensitizer. The areas 
proposed for clinical application of antimicrobial PDT 
include the treatment of chronic ulcers, infected burns, 
acne vulgaris and a variety of oral infections (Jori et al., 
2006). Furthermore the application of photodynamic 
reactions can be exploited to address environmental 
problems of high significance, including the decontami-
nation of waste waters, the disinfection of fish-farming 
tanks and the control of populations of noxious insects. 
Such diversified applications take advantage of the 
availability of a truly large number of porphyrin derivatives 
with chemical structures that can be tailored to comply 
with the physical and chemical properties, as well as the 
biological features of several environments. In addition, 
the unique property of porphyrins to absorb essentially all 
the wavelengths in the emission spectrum of the sun 
allows the promotion of processes largely based on 
natural light resources with significant energy saving and 





PDT is accepted as a treatment for a number of 
diseases, including several forms of cancer and some 
infectious diseases, and it is approved in many countries. 
In addition there has been an upsurge in the number of 
articles published on PDT each year, both clinical and 
basic. Therefore after several decades since its 
discovery, PDT is still an emerging technology with 
increasing potential. Many experimental investigations 
have been performed all over the world, some of them 
are duplicated. In recent times, the potential for clinical 
PDT in the developing world has been widely expressed 
in a number of reviews. Three of the major reasons given 
for this view include the cost-effectiveness of most of the 
PDT technologies,  low infrastructure  and equipment  re- 




quirements and the rapidly emerging effectiveness 
against Gram-negative and positive bacteria including 
those that are resistant to antibiotics. Probably due to the 
very low knowledge and awareness of PDT and 
associated technologies in the Developing World, there is 
very little or no clinical practice. Increasing the awareness 
and knowledge of these technologies will increase clinical 
practice in the Developing World. In the Developing 
World, PDT may be advanced among clinicians by con-
ducting extensive PDT awareness campaigns and re-
search, to provide the basis for rational programming and 
capital investment in key centres of excellence, in order 
to launch a focused effort in PDT. An important con-
tribution of these centres of excellence would be in emer-
ging applications of PDT in areas other than cancer and 
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